Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction-A Real-world Experience.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Sandmann, LisaDeppe, Julian
Beier, Christoph
Ohlendorf, Valerie
Schneider, Julia
Wedemeyer, Heiner
Wedegärtner, Felix
Cornberg, Markus
Maasoumy, Benjamin
Issue Date
2021-06-17
Metadata
Show full item recordCitation
Open Forum Infect Dis. 2021 Jun 17;8(8):ofab325. doi: 10.1093/ofid/ofab325.Affiliation
CiiM, Zentrum für individualisierte Infektionsmedizin, Feodor-Lynen-Str.7, 30625 Hannover.Journal
Open forum infectious diseasesPubMed ID
34377724Type
ArticleLanguage
enISSN
2328-8957ae974a485f413a2113503eed53cd6c53
10.1093/ofid/ofab325
Scopus Count
The following license files are associated with this item:
- Creative Commons
Related articles
- Direct-acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatment.
- Authors: Scherz N, Bruggmann P, Brunner N
- Issue date: 2018 Dec
- Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
- Authors: Petta S, Adinolfi LE, Fracanzani AL, Rini F, Caldarella R, Calvaruso V, Cammà C, Ciaccio M, Di Marco V, Grimaudo S, Licata A, Marrone A, Nevola R, Pipitone RM, Pinto A, Rinaldi L, Torres D, Tuttolomondo A, Valenti L, Fargion S, Craxì A
- Issue date: 2018 Jul
- Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.
- Authors: Bregenzer A, Conen A, Knuchel J, Friedl A, Eigenmann F, Näf M, Ackle P, Roth M, Fux CA
- Issue date: 2017
- Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
- Authors: Llaneras J, Riveiro-Barciela M, Lens S, Diago M, Cachero A, García-Samaniego J, Conde I, Arencibia A, Arenas J, Gea F, Torras X, Luis Calleja J, Antonio Carrión J, Fernández I, María Morillas R, Rosales JM, Carmona I, Fernández-Rodríguez C, Hernández-Guerra M, Llerena S, Bernal V, Turnes J, González-Santiago JM, Montoliu S, Figueruela B, Badia E, Delgado M, Fernández-Bermejo M, Iñarrairaegui M, Pascasio JM, Esteban R, Mariño Z, Buti M
- Issue date: 2019 Oct
- Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
- Authors: Sonderup MW, Gogela N, Nordien R, Smuts H, Korsman S, Hardie D, Spearman CW
- Issue date: 2020 Jan 29